Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Pharmaceuticals

Real-time Estimate Cboe Europe 11:58:13 2024-03-28 am EDT 5-day change 1st Jan Change
9.71 CHF +0.41% Intraday chart for Santhera Pharmaceuticals Holding AG +1.05% -2.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China MT
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment MT
Swiss Equities Edge Down After Central Banks Buzz MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers MT
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer CI
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy CI
Santhera, Catalyst Pharmaceuticals Secure US FDA Nod for Rare Neuromuscular Disease Drug MT
Catalyst Pharmaceuticals Says Santhera's Agamree Gains FDA Approval for Duchenne Muscular Dystrophy Treatment MT
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval DJ
US FDA approves Santhera's drug for rare muscular dystrophy RE
US FDA approves Santhera's Duschenne drug RE
Santhera Gets Positive Opinion From European Medicines Agency's Committee for Duchenne MD Drug MT
Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? for the Treatment of Duchenne Muscular Dystrophy CI
Transcript : Santhera Pharmaceuticals Holding AG, H1 2023 Earnings Call, Sep 07, 2023
Santhera Pharmaceuticals Narrows H1 Attributable Loss; Revenue Down MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Santhera Pharmaceuticals Closes Sale of Idebenone Business to Italy's Chiesi Farmaceutici MT
Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG. CI
Catalyst Pharmaceuticals Completes $75 Million Acquisition of Vamorolone's Exclusive License in North America MT
Santhera Grants Catalyst Pharmaceuticals Licensing Rights in North America for Vamorolone MT
Chart Santhera Pharmaceuticals Holding AG
More charts
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.67 CHF
Average target price
30 CHF
Spread / Average Target
+210.24%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Santhera Pharmaceuticals Holding AG - Swiss Exchange
  4. News Santhera Pharmaceuticals Holding AG
  5. Santhera to Restart Sales of Vision Loss Drug in France After Reimbursement Deal